Immunology and Biotherapies
25.0K views | +5 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade | Immunology and Biotherapies | Scoop.it
Loss of ADAR1 overcomes resistance to PD-1 checkpoint blockade caused by inactivation of antigen presentation by tumour cells. Thus, effective anti-tumour immunity is constrained by inhibitory checkpoints such as ADAR1 that limit the sensing of innate ligands. The induction of sufficient inflammation in tumours that are sensitized to interferon can bypass the therapeutic requirement for CD8+ T cell recognition of cancer cells and may provide a general strategy to overcome immunotherapy resistance.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

JCI Insight - Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Enhanced Natural Killer Cell Immunotherapy by Rationally Assembling Fc Fragments of Antibodies onto Tumor Membranes - Ji - - Advanced Materials - Wiley Online Library

Recent advances in cancer immunotherapy have exploited the efficient potential of natural killer (NK) cells to kill tumor cells through antibody‐dependent cell‐mediated cytotoxicity (ADCC). However, this therapeutic strategy is seriously limited by tumor antigen heterogeneity since antibodies can only recognize specific antigens. In this work, modified antibodies or their Fc fragments that can target solid tumors without the necessity of specific antigen presentation on tumors are developed. Briefly, Fc fragments or therapeutic monoclonal antibodies are conjugated with the N‐terminus of pH low insertion peptide so that they will selectively assemble onto the membrane of solid tumor cells via the conformational transformation of the peptide by responding to the acidic tumor microenvironment. The inserted Fc fragments or antibodies can efficiently activate NK cells, initiating ADCC and killing multiple types of tumor cells, including antigen‐negative cancer cells. In vivo therapeutic results also exhibit significant efficacy on both primary solid tumors and tumor metastasis. These modified Fc fragments and antibodies present strong potential to overcome the limitation of tumor antigen heterogeneity, broadening the applications of NK cell immunotherapy on solid tumor treatment.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sugar-transferring enzyme adds antibody to cell surface

Sugar-transferring enzyme adds antibody to cell surface | Immunology and Biotherapies | Scoop.it
Antibody tags along with enzyme’s natural substrate...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Harnessing NK Cell Memory for Cancer Immunotherapy - Dana-Farber Cancer Institute | Boston, MA

Harnessing NK Cell Memory for Cancer Immunotherapy - Dana-Farber Cancer Institute | Boston, MA | Immunology and Biotherapies | Scoop.it
Natural Killer (NK) cells are lymphoid cells with intrinsic antiviral and antitumor activity. NK cell function is normally regulated by key receptors, including inhibitory killer immunoglobulin-like receptors (KIRs), some of which recognize major histocompatibility complex (MHC) class I ligands. Prior clinical trials of NK cell products have met with limited success due to these cells' limited expansion, persistence, and activity after adoptive transfer.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Collaborative study for the establishment of human immunoglobulin BRP replacement batches. - PubMed - NCBI

Collaborative study for the establishment of human immunoglobulin BRP replacement batches. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Pharmeur Bio Sci Notes. 2018;2018:37-61.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Where next for cell-based therapy in ARDS

Where next for cell-based therapy in ARDS | Immunology and Biotherapies | Scoop.it
Acute respiratory distress syndrome (ARDS) is a form of acute hypoxaemic respiratory failure that is characterised by non-cardiogenic pulmonary oedema which occurs as a consequence of the breakdown of the alveolar–capillary unit.1 ARDS impacts more than 10% of all intensive care unit admissions,...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

An Efficient Method to Generate Monoclonal Antibodies from Human B Cells

An Efficient Method to Generate Monoclonal Antibodies from Human B Cells | Immunology and Biotherapies | Scoop.it
In the age of personalized medicine, an efficient method to generate monoclonal antibodies (mAbs) is essential for biomedical and immunotherapeutic research. Numerous aspects of basic B-cel
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

The success of immunotherapy has led to a myriad of new clinical trials. Connected to these trials are efforts to discover biomarkers providing mechanistic insight and predictive signatures for personalization. Still, the plethora of immune monitoring technologies can face investigator bias, missing unanticipated cellular responses in limited clinical material. We here present a mass cytometry workflow for standardized, systems-level biomarker discovery in immunotherapy trials. To broadly enumerate human immune cell identity and activity, we established and extensively assessed a reference panel of 33 antibodies to cover major cell subsets, simultaneously quantifying activation and immune checkpoint molecules in a single assay. The resulting assay enumerated ≥ 98% of peripheral immune cells with ≥ 4 positively identifying antigens. Robustness and reproducibility were demonstrated on multiple samples types, across research centers and by orthogonal measurements. Using automated analysis, we monitored complex immune dynamics, identifying signatures in bone-marrow transplantation associated graft-versus-host disease. This validated and available workflow ensures comprehensive immunophenotypic analysis, data comparability and will accelerate biomarker discovery in immunomodulatory therapeutics.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Comparison of reference Infliximab and a Biosimilar (CT-P13) in Crohn's Disease | Medpage Today

Comparison of reference Infliximab and a Biosimilar (CT-P13) in Crohn's Disease | Medpage Today | Immunology and Biotherapies | Scoop.it
Analysis of real-world data show that CT-P13 is equivalent to infliximab in infliximab-naive patients with CD...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

What’s gut got to do with it? How the gut microbiome affects cancer immunotherapy –

What’s gut got to do with it? How the gut microbiome affects cancer immunotherapy – | Immunology and Biotherapies | Scoop.it
Bacteria are virtually everywhere—on bus seats, on our hands, and even inside of our gut—but that isn’t necessarily a bad thing. These bacteria are part of the microbiome, the collection of microorganisms that live in or on an environment (such as the human body).
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape

Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape | Immunology and Biotherapies | Scoop.it
Regulatory T (Treg) cells are developed in the thymus, and are essential for suppressing detrimental autoimmunity. Here the authors show, using mice with dampened interleukin 2 (IL-2) signaling, that IL-2 helps position the pioneer factor SATB1 to control genome-wide chromatin accessibility to facilitate Treg cell lineage commitment in the thymus.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. - PubMed - NCBI

Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Cancer Res. 2018 Dec 12. pii: canres.1127.2018. doi: 10.1158/0008-5472.CAN-18-1127.[Epub ahead of print]...
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Vaccines: An achievement of civilization, a human right, our health insurance for the future

Vaccines: An achievement of civilization, a human right, our health insurance for the future | Immunology and Biotherapies | Scoop.it
Vaccines have made a key, cost-effective contribution to the prolongation of life expectancy and quality. Here we summarize challenges facing vaccinology and immunology at the level of society, scientific innovation, and technology in a global health perspective. We argue that vaccines represent a safety belt and life insurance for humankind.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

- Methods in Medical Informatics

- Methods in Medical Informatics | Immunology and Biotherapies | Scoop.it
Combination therapy with anti-HIV-1 antibodies Go to journal website Prediction of HIV-1 neutralization against bNAbs Go to journal website New NGS Geno2pheno go to journal website   Methods in Medical Informatics 27th of September 2018: Our proposal for an excellence cluster ‘Machine Learning: New Perspectives for Science’ where Nico is the PI for Machine Learning in Medicine got accepted, so we will have the excellence cluster in Tübingen starting January 1st 2019. See press release of the University of Tübingen. Go to cluster webpage 16th of August: Our latest research on data from a bNAbs trial was just accepted for publication at Nature Medicine (go to paper) 3rd of August: Our H2020 grant proposal CARE: “COMMON ACTION AGAINST HIV/TB/HCV ACROSS THE REGIONS OF EUROPE” was just accepted 30th of July 2018: Our latest analyses on data from a bNAbs trial were just accepted for publication at Nature (go to paper) 21st of April 2018: Our geno2pheno[ngs-freq] paper just got accepted at NAR (first author Matthias, last author Nico): [go to website] 8th of March 2018: Nico gave a keynote talk at the Workshop on Computational Models in Biology and Medicine 2018 in Regensburg Our (Anna and Nico) PLOS Comp Bio paper got the front cover of the November 2017 issue (predicting, visualizing and analyzing bNAbs resistance against HIV) 24th of October 2017: Our (Anna and Nico) paper on predicting, visualizing and analyzing bNAbs resistance against HIV was just published at PLOS Comp Bio. 29th of September 2017: Our proposal for an excellence cluster ‘Machine Learning: New Perspectives for Science’ where Nico is the PI for Machine Learning in Medicine made it to the next round. See press release of University of Tübingen. 22nd of August 2017: Sarvesh presented our latest work on machine learning methods for classification problems with variable length sequences at WABI. 10th of July 2017: The proposal of our consortium (DIFUTURE) within the medical informatics initiative of the BMBF was evaluated successfully: BMBF Website 6th of May 2017: Nico gave a talk at the Arevir meeting in Cologne. 18th of April 2017: Our paper on predicting long-range chromatin interactions (first author Sarvesh, last author Nico) just got published. 7th of March 2017: Nico gave a keynote talk at the 1st European Virus Bioinformatics Center meeting (http://evbc.uni-jena.de/meetings/1st-evbc-meeting/). 16th of January 2017: Our latest analysis of the 10-1074 trial was just published at Nature Medicine: Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. 1st of January 2017: Nico is now full professor for ‘Methods in Medical Informatics’ at the Department of Computer Science of the University of Tübingen. 20th of December: Our work (first author Matthias, last author Nico) on HIV-2 coreceptor usage prediction has just been published at Retrovirology: go to journal homepage 13th of December: Our latest analysis of the 10-1074 trial was just accepted at Nature Medicine. 9th of December: Nora gave a spotlight presentation at the NIPS workshop on Machine Learning for Health. 22nd of June: Our Nature paper (co-authors Anna and Nico) was just published: HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption 16th of June: Nico presented the 2016 research project funded by the supporting members of the Max Planck Society during the annual meeting of the Max Planck Society. 15th of June: Our manuscript submitted to Nature just got accepted. More details after the press embargo. 16th of May: Our Nature Medicine paper was just published: Impact of Pre-adapted HIV Transmission 5th of May 2016: Our Science paper (co-authors Anna and Nico) was just published: HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 The new semester started. Check out our lecture on Statistical Learning in Computational Biology. 27th of February 2016: Our paper on HLA footprints in transmitted HIV sequences got accepted at Nature Medicine. 2015 was a new max for program committee memberships. Nico was PC member of ISMB/ECCB 2015 (Disease models & Epidemiology track), ISMB/ECCB 2015 (Applied Bioinformatics track), MLCB 2015, GCB 2015, PSB 2016 (Precision Medicine track) , and Recomb 2016
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Selective Ablation of Tumorigenic Cells Following Human Induced Pluripotent Stem Cell‐Derived Neural Stem/Progenitor Cell Transplantation in Spinal Cord Injury - Kojima - - STEM CELLS Translational...

STEM CELLS Translational Medicine works to advance the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and helping speed translations of emerging lab discoveries into clinical trials, STEM CELLS Translational Medicine will help move applications of...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The clinical and pathological significance of borderline T cell‐mediated rejection - Nankivell - - American Journal of Transplantation - Wiley Online Library

The pathological diagnosis of borderline rejection (BL‐R) denotes possible T cell mediated rejection (TCMR), but its clinical significance is uncertain. This single‐centre, cross‐sectional cohort study compared the functional and histological outcomes of consecutive BL‐R diagnoses (n=146) against normal controls (n=826) and acute TCMR (n=55) from 551 renal transplant recipients. BL‐R was associated with: contemporaneous renal dysfunction, acute tubular necrosis and chronic tubular atrophy (P<0.001); progressive tubular injury with fibrosis by longitudinal sequential histology (45.3% at 1 year); increased subsequent acute rejection (39.4%), allograft failure (P<0.001), and patient mortality (P=0.007). BL‐R detected by biopsy indicated for impaired function was followed by suboptimal functional recovery (46.3%), persistent inflammation (27.2%), and acute rejection episodes (50.0%) despite anti‐rejection treatment in 83.3%. By one year after BL‐R, the incidence of new‐onset microvascular inflammation (9.3%), C4d staining (22.3%), transplant glomerulopathy (13.3%), and de novo donor specific antibodies (31.5%) exceeded normal controls (P<0.05‐0.001). BL‐R inflammation in protocol biopsy persisted in 28.0% and progressed to acute rejection in 32.6%, however resolved in 61.6% of the untreated cases. In summary, BL‐R is a heterogeneous diagnostic grouping, ranging from mild inconsequential inflammation to clinically‐significant TCMR, which is capable of immune‐mediated tubular injury resulting in inferior functional, immunological and histological consequences. This article is protected by copyright. All rights reserved.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors | Immunology and Biotherapies | Scoop.it
Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting in autoantibody formation, which could be associated with immune-related adverse events (irAEs) and antitumor efficacy. Twenty-three common clinical autoantibodies in pre- and posttreatment sera from 133 ipilimumab-treated melanoma patients were determined, and their development linked to the occurrence of irAEs, best overall response, and survival. Autoantibodies developed in 19.2% (19/99) of patients who were autoantibody-negative pretreatment. A nonsignificant association was observed between development of any autoantibodies and any irAEs [OR, 2.92; 95% confidence interval (CI) 0.85–10.01]. Patients with antithyroid antibodies after ipilimumab had significantly more thyroid dysfunction under subsequent anti–PD-1 therapy: 7/11 (54.6%) patients with antithyroid antibodies after ipilimumab developed thyroid dysfunction under anti–PD1 versus 7/49 (14.3%) patients without antibodies (OR, 9.96; 95% CI, 1.94–51.1). Patients who developed autoantibodies showed a trend for better survival (HR for all-cause death: 0.66; 95% CI, 0.34–1.26) and therapy response (OR, 2.64; 95% CI, 0.85–8.16). We conclude that autoantibodies develop under ipilimumab treatment and could be a potential marker of ICI toxicity and efficacy.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Human Monoclonal Antibodies: The Benefits of Humanization

Human Monoclonal Antibodies: The Benefits of Humanization | Immunology and Biotherapies | Scoop.it
The major reasons for developing human monoclonal antibodies were to be able to efficiently manipulate their effector functions while avoiding immunogenicity seen with rodent antibodies

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Development of a monoclonal antibody based-ELISA for the detection of chloramphenicol in shrimp, feed and milk samples and validated by LC-MS/MS coupled with immunoaffinity clean-up - Analytical Me...

In this study, a monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA) for the determination of chloramphenicol (CAP) in shrimp, feed and milk samples was developed, and validated by LC-MS/MS coupled with immunoaffinity clean-up (LC-MS/MS-IAC).
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Regulating the gene-therapy revolution

Regulating the gene-therapy revolution | Immunology and Biotherapies | Scoop.it
The medical regulatory authorities ride a wave of clinical studies for gene therapies.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Phase I Promise for Netrin Pharma's First-in-Class Antibody Cancer Treatment

Phase I Promise for Netrin Pharma's First-in-Class Antibody Cancer Treatment | Immunology and Biotherapies | Scoop.it
A first-in-class antibody cancer treatment, from the French company Netris Pharma, has shown good safety and anti-tumor effects in a phase I trial in patients with advanced solid tumors.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Tasuku Honjo - Nobel Lecture: Serendipities of acquired immunity

Tasuku Honjo - Nobel Lecture: Serendipities of acquired immunity | Immunology and Biotherapies | Scoop.it
The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? | Immunology and Biotherapies | Scoop.it
A new interesting article has been published in Cancer Treat Rev. 2018 Dec;71:47-58. doi: 10.1016/j.ctrv.2018.10.006. Epub 2018 Oct 15.Review and titled: Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the …...
more...
No comment yet.